Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Melanoma 31Carcinoma, Renal Cell 19Carcinoma, Non-Small-Cell Lung 19Neoplasm Metastasis 11Carcinoma, Hepatocellular 9Brain Neoplasms 8Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Pancreatic Neoplasms 5Lung Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Transitional Cell 5Uveal Melanoma 4Skin Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Multiple Myeloma 4Mesothelioma 4Kidney Neoplasms 4Glioblastoma 4Carcinoma, Basal Cell 4Carcinoma 4Sarcoma 3Recurrence 3Myelodysplastic Syndromes 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Gliosarcoma 3Colorectal Neoplasms 3Breast Neoplasms 3

Interventions

cabozantinib 1Specimen Handling 1Platinum Compounds 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Scleroderma, Systemic × Ipilimumab × 90 days × Clear all
NCT03816345 2026-05-13

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

National Cancer Institute (NCI)

Phase 1 Recruiting
300 enrolled
Other hematologic neoplasm

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡